Abstract | BACKGROUND: METHODS: FINDINGS: 5380 patients were assigned to alogliptin (n=2701) or placebo (n=2679) and followed up for a median of 533 days (IQR 280-751). The exploratory extended MACE endpoint was seen in 433 (16·0%) patients assigned to alogliptin and in 441 (16·5%) assigned to placebo (hazard ratio [HR] 0·98, 95% CI 0·86-1·12). Hospital admission for heart failure was the first event in 85 (3·1%) patients taking alogliptin compared with 79 (2·9%) taking placebo (HR 1·07, 95% CI 0·79-1·46). Alogliptin had no effect on composite events of cardiovascular death and hospital admission for heart failure in the post hoc analysis (HR 1·00, 95% CI 0·82-1·21) and results did not differ by baseline BNP concentration. NT-pro-BNP concentrations decreased significantly and similarly in the two groups. INTERPRETATION: FUNDING: Takeda Development Center Americas.
|
Authors | Faiez Zannad, Christopher P Cannon, William C Cushman, George L Bakris, Venu Menon, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer, Craig Wilson, Hung Lam, William B White, EXAMINE Investigators |
Journal | Lancet (London, England)
(Lancet)
Vol. 385
Issue 9982
Pg. 2067-76
(May 23 2015)
ISSN: 1474-547X [Electronic] England |
PMID | 25765696
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2015 Elsevier Ltd. All rights reserved. |
Chemical References |
- Hypoglycemic Agents
- Peptide Fragments
- Piperidines
- pro-brain natriuretic peptide (1-76)
- Natriuretic Peptide, Brain
- Uracil
- alogliptin
|
Topics |
- Acute Coronary Syndrome
(prevention & control)
- Aged
- Angina, Unstable
(etiology)
- Diabetes Mellitus, Type 2
(prevention & control)
- Diabetic Cardiomyopathies
(prevention & control)
- Double-Blind Method
- Female
- Heart Failure
(chemically induced)
- Hospitalization
(statistics & numerical data)
- Humans
- Hypoglycemic Agents
(adverse effects)
- Male
- Middle Aged
- Myocardial Infarction
(chemically induced)
- Natriuretic Peptide, Brain
(metabolism)
- Peptide Fragments
(metabolism)
- Piperidines
(adverse effects)
- Risk Factors
- Stroke
(chemically induced)
- Uracil
(adverse effects, analogs & derivatives)
|